Synthesis and anti-tumor application of erianin derivative

Abstract

The invention belongs to the field of medicines, and particularly relates to a preparation method and anti-tumor application of a novel erianin derivative. The erianin derivative with a novel structure is prepared by adopting a simple and efficient synthesis method, and the specific structural general formula is as follows: imgabs0 #. The research on the in-vitro anti-tumor activity of the compound in the invention shows that the novel erianin derivative has an obvious inhibition effect on the growth of human breast cancer cells (MDA-MB-231) and human gastric cancer cells (SGC7901); therefore, the erianin derivative can be used as a lead compound or a candidate compound for the development of antitumor drugs.

Description

Technical Field

[0001] The invention belongs to the field of medicine, and specifically relates to the synthesis and anti-tumor application of a novel Erianin derivative. Background Art

[0002] Cancer is the second leading cause of death in developing countries. Currently, chemotherapy drugs include alkylating agents (cyclophosphamide), antibiotics (doxorubicin), etc. Since these chemotherapy drugs have no difference in effect on tumors and normal cells, they have side effects, such as neurotoxicity. Therefore, it is very necessary to develop new anti-tumor drugs with better efficacy and less toxic side effects. As one of the natural products derived from Dendrobium officinale, Erianin has significant pharmacological effects such as anticancer, antibacterial, and antioxidant. In recent years, Erianin has been shown to have significant anti-tumor effects on various types of cancer in vivo and in vitro through various mechanisms, and is considered to be a potential anti-cancer molecule. However, Erianin has the disadvantages of low solubility, rapid metabolism, and poor bioavailability, which makes it impossible to become an efficient and low-toxic anti-tumor drug. Therefore, the development of new Erianin derivatives based on Erianin and the study of its anti-tumor activity have very important research value, which is conducive to the development of drugs with independent intellectual property rights in my country. Summary of the invention

[0003] The present invention aims to provide an Erianin derivative with a novel structure and a simple preparation method. Another object of the present invention is to provide its application in anti-tumor drugs.

[0004] To achieve the above purpose, the general structural formula of the Erianin derivatives of the present invention is as follows:

[0005]

[0006] In the structure shown in the general formula I, R is 3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3-nitro-4-methoxyphenyl, 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl; R 1 is 3,4,5-trimethoxyphenyl, 4-methoxyphenyl; R 2 is 4-fluorobenzoylhydrazide or benzoylhydrazide; X is

[0007]

[0008] Preferably, the structure of the Erianin derivative is as follows:

[0009]

[0010] The present invention also provides a preparation method of the above-mentioned Erianin derivative, comprising the following steps: firstly, a substitution reaction is carried out between a substituted benzyl bromide WCJ-05 and a substituted aniline WCJ-01 in acetone to prepare a compound WCJ-02; the compound WCJ-02 is reacted with methyl 4-chloroformylbenzoate or methyl 4-bromomethylbenzoate or methyl succinate chloride or monomethyl oxalyl chloride to prepare a compound WCJ-03; the compound WCJ-03 is hydrolyzed with an aqueous sodium hydroxide solution to prepare a compound WCJ-04; and the compound WCJ-04 is condensed with 4-fluorobenzoylhydrazide or benzoylhydrazide to prepare a target product, the Erianin derivative.

[0011] The synthetic route is as follows:

[0012]

[0013] The present invention also provides the use of any one of the above compounds in the preparation of tumor drugs. Preferably, the tumor is selected from human breast cancer cells (MDA-MB-231) and human gastric cancer cells (SGC7901).

[0014] The present invention also provides an anti-tumor drug, comprising any one of the above-mentioned Erianin derivatives and a pharmaceutically acceptable carrier, a pharmaceutically acceptable salt and an excipient.

[0015] The present invention has the following beneficial effects:

[0016] The invention provides a novel Erianin derivative.

[0017] The invention provides a method for synthesizing an Erianin derivative. The method is simple and safe to operate, has few reaction by-products, high yield, and is easy to separate and purify.

[0018] The in vitro anti-tumor activity experiment of the novel Erianin derivatives of the present invention found that the compounds had strong inhibitory activity against human gastric cancer cells (SGC-7901), and the strongest inhibitory activity IC 50 The value is 23nM, which has broad application prospects in the preparation of anti-tumor drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0020] Figure 1 For compound (WCJ-02-3) 1 H-NMR

[0021] Figure 2 For compound (WCJ-02-3) 13 C-NMR

[0022] Figure 3 HRMS of compound (WCJ-02-3) DETAILED DESCRIPTION

[0023] The following will be clearly and completely described in conjunction with the technical solutions in the specific embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. The following description of at least one exemplary embodiment is actually only illustrative and is by no means intended to limit the present invention and its application or use. Based on the embodiments of the present invention, other embodiments obtained by ordinary technicians in this field without creative work are all within the scope of protection of the present invention.

[0024] The structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). The NMR measurement uses a Bruker AV-500 nuclear magnetic spectrometer, the measurement solvent is deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3) and deuterated methanol (CD3OD), and the internal standard is tetramethylsilane (TMS). The chemical shift (δ) unit is ppm.

[0025] Examples of compound synthesis

[0026] Example 1: Preparation of N-(3,4-dimethoxybenzyl)-4-(2-(4-fluorobenzoyl)hydrazine-1-carbonyl)-N-(3,4,5-trimethoxyphenyl)benzamide (WCJ-02-17)

[0027] Preparation of 3,4,5-trimethoxy-N-(3,4-dimethoxybenzyl)aniline (WCJ-02)

[0028] In a 100 mL round-bottom flask, add 3,4,5-trimethoxyaniline (5.38 g, 29.37 mmol), 3,4-dimethoxybenzyl bromide (6.79 g, 29.37 mmol), potassium carbonate (4.46 g, 32.30 mmol) and 60 mL of acetone, heat to reflux and react for 8 h. Monitor the completion of the reaction by TLC, stop the reaction, extract with dichloromethane and saturated brine, retain the organic phase, dry over anhydrous sodium sulfate, distill under reduced pressure, and separate by silica gel column chromatography (eluent: petroleum ether: ethyl acetate = 15:1) to obtain intermediate WCJ-02.

[0029] Preparation of methyl 4-((3,4-dimethoxybenzyl)(3,4,5-trimethoxyphenyl)carbamoyl)benzoate (WCJ-03)

[0030] To a 100 mL round-bottom flask containing the intermediate WCJ-02 (5 g, 15.00 mmol), 50 mL of dichloromethane and N, N-diisopropylethylamine (5.74 mL, 32.96 mmol) were added. The mixture was cooled to 0°C in an ice-water bath. 10 mL of dichloromethane containing methyl 4-chloroformylbenzoate (3.6 g, 18.00 mmol) was slowly added dropwise and stirred for reaction. The reaction was stopped after monitoring by TLC. The mixture was extracted with dichloromethane and saturated brine, and the organic phase was retained. The phase was dried over anhydrous sodium sulfate, evaporated under reduced pressure, and separated by silica gel column chromatography (eluent: dichloromethane: methanol = 40:1) to obtain the intermediate WCJ-03 (6.2 g, 79%).

[0031] Preparation of 4-((3,4-dimethoxybenzyl)(3,4,5-trimethoxyphenyl)carbamoyl)benzoic acid (WCJ-04)

[0032] To a 50 mL round-bottom flask containing the intermediate WCJ-03 (4 g, 8.59 mmol), 20 mL of methanol and 5 mL of water were added, stirred at room temperature to dissolve, and 3 mL of aqueous solution of sodium hydroxide (378 mg, 9.45 mmol) was added, stirred at room temperature to react, and the reaction was completed after monitoring by TLC. The reaction was stopped and distilled under reduced pressure. Ethyl acetate and water were added for extraction, and the aqueous phase was retained. 1 M hydrochloric acid was used to adjust the pH to 1. The organic phase was extracted with dichloromethane and dried over anhydrous sodium sulfate. The intermediate WCJ-04 (3.4 g, 88%) was obtained by distillation under reduced pressure.

[0033] Preparation of N-(3,4-dimethoxybenzyl)4-(2-(4-fluorobenzoyl)hydrazine-1-carbonyl)-N-(3,4,5-trimethoxyphenyl)benzamide (WCJ-02-17)

[0034] The intermediate WCJ-04 (250 mg, 553.74 μmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (143.83 mg, 609.11 μmol), and 1-hydroxybenzotriazole (68.32 mg, 609.11 μmol) were added to a 25 mL round-bottom flask containing 10 mL of dichloromethane and stirred at room temperature for 30 minutes. 4-Fluorobenzohydrazide (151 mg, 0.98 mmol) was added to react. The reaction was monitored by TLC. The reaction was stopped, and dichloromethane and water were added for extraction. The organic phase was retained, dried over anhydrous sodium sulfate, distilled under reduced pressure, and separated by silica gel column chromatography (eluent: dichloromethane: methanol = 40:1) to obtain the target product WCJ-02-17 as a white solid.

[0035] White solid, yield: 67.7%. mp 98.5-99.5℃. 1H NMR (400MHz, CDCl3) δ9.34 (d, J=4.6Hz, 1H), 9.22 (s, 1H), 7.88-7.84 (m, 2H), 7.68 (d, J=8.3Hz, 2H), 7.44 (d, J=8.4Hz, 2H), 7.1 6-7.09 (m, 2H), 6.90 (s, 1H), 6.85-6.78 (m, 2H), 6.08 (s, 2H), 5.00 (s, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 3.77 (s, 3H), 3.58 (s, 6H). 13 C NMR (101MHz, CDCl3) δ169.26, 166.48, 164.28, 164.16, 163.96, 153.23, 148.94, 148.61, 140.17, 138.23, 137.16, 131.97, 129.93, 129.8 4, 128.46, 127.36, 127.33, 126.95, 121.37, 115.90, 115.68, 112.16, 110.95, 105.66, 60.97, 56.16, 55.92, 53.77. HR-MS (ESI) m / z: calcd for C 33 H 33 N3O9Na[M+Na] + 634.2205, found 634.2201.

[0036] Example 2: Preparation of N-(3-fluoro-4-methoxybenzyl)-4-(2-(4-fluorobenzoyl)hydrazine-1-carbonyl)-N-(3,4,5-trimethoxyphenyl)benzamide (WCJ-02-21)

[0037] 3-Fluoro-4-methoxybenzyl bromide was used to replace 3,4-dimethoxybenzyl bromide. The preparation method was the same as that in Example 1.

[0038] White solid, yield: 75%. mp100.2-101.2℃. 1 H NMR (400MHz, CDCl3) δ9.36 (s, 1H), 9.27 (s, 1H), 7.89-7.82 (m, 2H), 7.67 (d, J=8.1Hz, 2H), 7.44 (d, J=8.0Hz, 2H), 7.12 (t, J= 8.6Hz, 3H), 7.01 (d, J=8.3Hz, 1H), 6.89 (t, J=8.5Hz, 1H), 6.08 (s, 2H), 4.98 (s, 2H), 3.88 (s, 3H), 3.77 (s, 3H), 3.60 (s, 6H). 13C NMR (101MHz, CDCl3) δ169.31, 166.49, 164.25, 164.16, 163.97, 153.39, 15 3.33, 150.94, 147.24, 147.13, 139.89, 138.03, 137.24, 132.07, 130.15, 12 9.93, 129.84, 128.52, 127.35, 126.96, 124.82, 116.69, 116.51, 115.91, 1 15.69, 113.20, 105.53, 60.98, 56.27, 56.18, 53.23. HR-MS (ESI) m / z: calcd for C 32 H 29 N3O7F2Na[M+Na] + 628.1871, found 628.1871.

[0039] Example 3: Preparation of 4-(2-(4-fluorobenzoyl)hydrazine-1-carbonyl)-N-(4-methoxy-3-nitrobenzyl)-N-(3,4,5-trimethoxyphenyl)benzamide (WCJ-02-19)

[0040] 4-methoxy-3-nitrobenzyl bromide was used to replace 3,4-dimethoxybenzyl bromide. The preparation method was the same as that in Example 1.

[0041] White solid, yield: 72.8%. mp 120.8-121.8℃. 1 H NMR (400MHz, CDCl3) δ9.31 (d, J = 5.3Hz, 1H), 9.28 (s, 1H), 7.85 (ddd, J = 10.0, 5.2, 2.6Hz, 2H), 7.79 (d, J = 2.3Hz, 1H), 7.68 (d, J = 8.4Hz, 2H), 7.58 (dd, J = 8.3, 2.1Hz, 1H), 7.44 (d, J=8.4Hz, 2H), 7.13 (t, J=8.6Hz, 2H), 7.05 (d, J=8. 7Hz, 1H), 6.11 (s, 2H), 5.04 (s, 2H), 3.96 (s, 3H), 3.78 (s, 3H), 3.63 (s, 6H). 13C NMR (101MHz, CDCl3) δ169.34, 164.01, 163.93, 153.57, 152.40, 139.5l, 139.37, 137.86, 137.46, 134.86, 132.24, 129.88, 129.7 9, 129.56, 128.63, 127.35, 126.97, 125.95, 116.00, 115.78, 113.65, 105.48, 61.02, 56.61, 56.25, 52.94. HR-MS (ESI) m / z: calcd forC 32 H 29 N4O9FNa[M+Na] + 655.1816, found 655.1816.

[0042] Example 4: Preparation of 4-(2-(4-fluorobenzoyl)hydrazine-1-carbonyl)-N-(4-methoxybenzyl)-N-(3,4,5-trimethoxyphenyl)benzamide (WCJ-02-3)

[0043] 4-methoxybenzyl bromide was used to replace 3,4-dimethoxybenzyl bromide. The preparation method was the same as that in Example 1.

[0044] White solid, yield: 72%. mp 108.5-109.5℃. 1 H NMR (500MHz, CDCl3) δ9.52 (s, 1H), 9.28 (s, 1H), 7.77 (d, J = 8.2Hz, 2H), 7.65 (d, J = 7.9Hz, 2H), 7.41 (dd, J = 11.2, 8.3Hz , 4H), 7.24 (d, J=7.9Hz, 2H), 6.84 (d, J=8.2Hz, 2H), 6.06 (s, 2H), 5.00 (s, 2H), 3.79 (s, 3H), 3.76 (s, 3H), 3.57 (s, 6H). 13 C NMR (101MHz, CDCl3) δ169.31, 166.47, 164.40, 164.26, 163.94, 159.14, 153.21, 140.16, 138.13, 137.12, 131.94, 130.20, 129.96, 12 9.87, 129.39, 128.45, 127.41, 127.37, 126.94, 115.87, 115.65, 113.89, 105.68, 60.96, 56.14, 55.28, 53.43. HR-MS (ESI) m / z: calcd for C 32 H 30N3O7NaF[M+Na] + 610.1969, found 610.1965.

[0045] Example 5: Preparation of 4-(2-(4-fluorobenzoyl)hydrazine-1-carbonyl)-N-(4-methoxyphenyl)-N-(3,4,5-trimethoxybenzyl)benzamide (WCJ-02-18)

[0046] 3,4,5-trimethoxybenzyl bromide was used to replace 3,4-dimethoxybenzyl bromide, and 4-methoxyaniline was used to replace 3,4,5-trimethoxyaniline. The preparation method was the same as that in Example 1.

[0047] White solid, yield: 56.9%. mp 107.5-108.5℃. 1 H NMR (400MHz, CDCl3) δ9.48 (s, 1H), 9.22 (s, 1H), 7.87-7.82 (m, 2H), 7.63 (d, J = 8.0Hz, 2H), 7.37 (d, J = 8.0Hz, 2H), 7.10 (t, J=8.6Hz, 2H), 6.79 (d, J=8.4Hz, 2H), 6.69-6.65 (m, 2H), 6.50 (s, 2H), 4.98 (s, 2H), 3.84 (s, 3H), 3.78 (s, 6H), 3.72 (s, 3H). 13 C NMR (101MHz, CDCl3) δ169.48, 166.44, 164.59, 164.28, 163.92, 158.44, 153.17, 140.09, 137.42, 135.27, 132.76, 131.75, 129.96, 12 9.87, 129.18, 128.74, 127.32, 127.29, 126.90, 115.82, 115.61, 114.40, 105.93, 60.88, 56.12, 55.32, 54.17. HR-MS (ESI) m / z: calcd for C 32 H 30 N3O7FNa[M+Na] + 610.1965, found 610.1965.

[0048] Example 6: Preparation of 2-(2-(4-fluorobenzoyl)hydrazino)-N-(4-methoxybenzyl)-2-oxo-N-(3,4,5-trimethoxyphenyl)acetamide (WCJ-02-22)

[0049] The preparation method is the same as that in Example 1 except that 4-methoxybenzyl bromide is used to replace 3,4-dimethoxybenzyl bromide and methyl oxalyl chloride is used to replace methyl 4-chloroformylbenzoate.

[0050] White solid, yield: 42.4%. mp 98.5-99.5℃. 1 H NMR (400MHz, CDCl3) δ9.57 (d, J = 5.4Hz, 1H), 8.58 (d, J = 5.2Hz, 1H), 7.74 (dd, J = 8.8, 5.2Hz, 2H), 7.16 (d, J = 8.6Hz, 2 H), 7.08 (t, J=8.6Hz, 2H), 6.82 (d, J=8.6Hz, 2H), 6.20 (s, 2H), 4.85 (s, 2H), 3.82 (s, 3H), 3.79 (s, 3H), 3.71 (s, 6H). 13 C NMR (101MHz, CDCl3) δ165.76, 165.46, 163.78, 161.65, 159.43, 157.59, 153.27, 137.71, 135.38, 130.57, 130.22, 13 0.02, 129.95, 129.58, 129.28, 116.00, 115.82, 113.86, 104.47, 60.96, 56.13, 55.29, 54.89. HR-MS (ESI) m / z: calcd forC 26 H 26 N3O7FNa [M+Na] + 534.1657, found 534.1653

[0051] Example 7: Preparation of 4-(2-(4-fluorobenzoyl)hydrazino)-N-(4-methoxybenzyl)-4-oxo-N-(3,4,5-trimethoxyphenyl)butyramide (WCJ-02-23)

[0052] The preparation method is the same as that in Example 1 except that 4-methoxybenzyl bromide is used to replace 3,4-dimethoxybenzyl bromide and methyl succinate chloride is used to replace methyl 4-chloroformylbenzoate.

[0053] White solid, yield: 18.3%. mp 84.5-85.5℃. 1H NMR (400MHz, CDCl3) δ8.78 (s, 1H), 7.87-7.82 (m, 2H), 7.15-7.07 (m, 5H), 6.79-6.77 (m, 2H), 6.20 (s , 2H), 4.78 (s, 2H), 3.84 (s, 3H), 3.75 (s, 3H), 3.71 (s, 6H), 2.67-2.63 (m, 2H), 2.53 (t, J=5.9Hz, 2H). 13 C NMR (101MHz, CDCl3) δ172.00, 171.26, 166.34, 164.24, 163.82, 159.03, 153.61, 137.81, 137.14, 130.32, 129.89, 129.80, 1 29.46, 128.00, 127.97, 115.80, 115.58, 113.71, 105.75, 60.95, 56.19, 55.24, 52.62, 29.53, 29.32. HR-MS (ESI) m / z: calcd for C 28 H 30 N3O7FNa[M+Na] + 562.1970, found 562.1965.

[0054] Example 8: Preparation of 4-fluoro-N'-(4-((4-methoxybenzyl)(3,4,5-trimethoxyphenyl)amino)methyl)benzoyl)benzoylhydrazide (DX-30-01)

[0055] The preparation method is the same as that in Example 1 except that 4-methoxybenzyl bromide is used to replace 3,4-dimethoxybenzyl bromide and 4-bromomethylbenzoic acid methyl ester is used to replace 4-chloroformylbenzoic acid methyl ester.

[0056] White solid, yield: 80.9%. mp 136.5-137.5℃. 1 H NMR (400MHz, CDCl3) δ9.70 (s, 1H), 9.44 (s, 1H), 7.89-7.85 (m, 2H), 7.81 (d, J = 8.3Hz, 2H), 7.33 (d, J = 7.8Hz, 2H), 7.26 (s, 2H), 7.17 (d, J = 8. 8Hz, 2H), 7.08 (td, J = 8.6, 1.6Hz, 2H), 6.87 (d, J = 8.8Hz, 2H), 5.94 (s, 2H), 4.58 (s, 2H), 4.52 (s, 2H), 3.80 (s, 3H), 3.75 (s, 3H), 3.68 (s, 6H). 13C NMR (101MHz, CDCl3) δ166.48, 164.99, 164.04, 163.96, 158.81, 153.74, 145.93, 144.20, 130.28, 130.18, 129.94, 129. 90, 129.81, 128.15, 127.75, 127.37, 127.12, 115.89, 115.67, 114.12, 91.53, 61.06, 55.97, 55.30, 54.80, 54.62.HR-MS (ESI)m / z: calcd for C 32 H 33 N3O6F [M+H] + 574.2353, found 574.2353.

[0057] Example 9: Preparation of N'-benzoyl 4-(((4-methoxybenzyl)(3,4,5-trimethoxyphenyl)amino)methyl)benzohydrazide (DX-33-01)

[0058] The preparation method is the same as that in Example 1 except that 4-methoxybenzyl bromide is used to replace 4'4-dimethoxybenzyl bromide, 4-bromomethylbenzoic acid methyl ester is used to replace 4-chloroformylbenzoic acid methyl ester, and benzohydrazide is used to replace 4-fluorobenzohydrazide.

[0059] White solid, yield: 37.4%. mp 115-116℃. 1 H NMR (400MHz, CDCl3) δ9.41 (q, J=6.3Hz, 2H), 7.88-7.82 (m, 4H), 7.58-7.53 (m, 1H), 7.45 (t, J=7.6Hz, 2H), 7.35 (d, J=8.0Hz, 2 H), 7.18 (d, J=8.6Hz, 2H), 6.89-6.85 (m, 2H), 5.95 (s, 2H), 4.59 (s, 2H), 4.53 (s, 2H), 3.80 (s, 3H), 3.76 (s, 3H), 3.68 (s, 6H). 13 C NMR (101MHz, CDCl3) δ164.40, 164.04, 158.81, 153.74, 132.49, 131.28, 130.07, 128.78, 128.17, 1 27.70, 127.28, 127.18, 114.12, 91.51, 61.07, 55.98, 55.32, 54.80, 54.70. HR-MS (ESI) m / z: calcd for C 32 H 34 N3O6[M+H] +556.2448, found 556.248.

[0060] Application examples of compounds

[0061] In vitro anti-tumor activity test: Four cell lines were used using the CCK8 method, namely human breast cancer cells (MDA-MB-231) and human gastric cancer cells (SGC-7901).

[0062] Collect cells in the logarithmic phase, adjust the concentration of the cell suspension, add 100 μL to each well, plate to adjust the cell density to be tested, and fill the edge wells of the 96-well plate with PBS. Incubate for 24 hours under 5% CO2, 37°C, and 90% humidity conditions until the cell monolayer covers the bottom of the 96-well plate. Add the drug synthesized by the present invention with a concentration gradient, set 9 concentrations, 200 μL in the mother well, set 3 replicate wells, incubate for 72 hours, observe under an inverted microscope, add 10 μL of CCK8 solution to each well, and continue to culture for 2 hours. Use an enzyme reader to measure the absorbance of each well at 450nm. Use GraphPad Prism 9.5 software to count the experimental results and calculate the IC 50 (μmol / L) values, the results are shown in Table 1 below.

[0063] Table 1 In vitro antitumor activity test results

[0064]

Claims

1. A novel Erianin derivative, characterized in that: It has the structure described by general formula I: In the general formula I: R is 3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3-nitro-4-methoxyphenyl, 4-methoxyphenyl, 3-fluoro-4-methoxyphenyl; R 1 is 3,4,5-trimethoxyphenyl or 4-methoxyphenyl; R 2 is 4-fluorobenzoylhydrazide or benzoylhydrazide; X is 2. The Erianin derivative according to claim 1, characterized in that: Select one of the following compounds:

3. A method for preparing the Erianin derivative according to claim 1, characterized in that: This is achieved through the following synthetic steps: First, the substituted benzyl bromide WCJ-05 and the substituted aniline WCJ-01 undergo a substitution reaction in acetone to prepare compound WCJ-02; compound WCJ-02 reacts with 4-chloroformylbenzoic acid methyl ester or 4-bromomethylbenzoic acid methyl ester or succinic acid methyl chloride or oxalyl chloride monomethyl ester to prepare compound WCJ-03; compound WCJ-03 undergoes a hydrolysis reaction with a sodium hydroxide aqueous solution to prepare compound WCJ-04; compound WCJ-04 undergoes a condensation reaction with 4-fluorobenzoylhydrazide or benzoylhydrazide to prepare the target product, an Erianin derivative.

4. The use of the Erianin derivative in drug preparation according to claim 1, characterized in that: It is used as an active ingredient in the preparation of drugs against breast cancer cells and gastric cancer.

5. An anti-tumor drug composition, characterized in that: The pharmaceutical composition uses the compound described in claim 1 as an active ingredient; the pharmaceutical composition also includes a pharmaceutically acceptable carrier, a pharmaceutical salt or an excipient.

Images